09:07 AM EDT, 10/17/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that a phase III trial showed adding one year of Imfinzi treatment to Bacillus Calmette-Guerin induction and maintenance therapy cut the risk of disease recurrence or death by 32% compared with BCG alone.

The company also said that with the Imfinzi regimen, an estimated 87% of patients remained alive and disease-free at two years compared with 82% with BCG alone.

The trial's primary endpoint was disease-free survival for Imfinzi plus BCG induction and maintenance therapy compared with BCG induction and maintenance therapy alone, the company said.

AstraZeneca ( AZN ) said the trial's secondary endpoints included disease-free survival for Imfinzi plus BCG induction only therapy versus the comparison group, and overall survival at five years and safety in both experimental arms.

The Imfinzi regimen's safety and tolerability were consistent with the individual medicines' safety profiles, the company said.